2. Induced Disease Models Products Others Metabolic Enzyme/Protease
  3. Endocrine and Metabolic Disease Models Five Sense Organs Disease Models Environmental Pollutants Endogenous Metabolite
  4. Aging Models
  5. D-Galactose

D-Galactose  (Synonyms: D-(+)-Galactose)

Cat. No.: HY-N0210 Purity: 99.85%
COA
SDS
Handling Instructions Technical Support

D-Galactose is a natural aldohexose and C-4 epimer of glucose.

For research use only. We do not sell to patients.

CAS No. : 59-23-4

Size Price Stock Quantity
100 mg In-stock
500 mg In-stock
1 g In-stock
5 g In-stock
10 g In-stock
25 g In-stock
50 g In-stock
100 g In-stock
> 100 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 27 publication(s) in Google Scholar

Other Forms of D-Galactose:

D-Galactose Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
IF
WB

    D-Galactose purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Dec 30;339(Pt 2):149976.  [Abstract]

    D-galactose (D-Gal) (300 μg/mL, 72 h). Cell viability of KGN and SVOG cells in different groups.

    D-Galactose purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Dec 30;339(Pt 2):149976.  [Abstract]

    D-galactose (D-Gal) (300 μg/mL, 72 h). Detection of p21 protein levels in KGN and SVOG cells of each group.

    D-Galactose purchased from MedChemExpress. Usage Cited in: J Cachexia Sarcopenia Muscle. 2024 May 16.  [Abstract]

    CCK8 was used to detect the cell viability of porcine MuSCs treated with D-gal (0, 1, 5, 10, 20, 40 g/L; 48 h). (n = 5)

    D-Galactose purchased from MedChemExpress. Usage Cited in: J Cachexia Sarcopenia Muscle. 2024 May 16.  [Abstract]

    Immunofluorescence staining with γH2AX (green) and DAPI (blue) was detected in C2C12 treated with 10 ng/ml FGF7 recombinant protein, 20 g/L D-gal, 20 g/L D-gal + 10 ng/ml FGF7, and the nuclear area (n = 200 nuclei) and ratio of γH2AX+ cells (n = 3) were quantified.

    D-Galactose purchased from MedChemExpress. Usage Cited in: J Cachexia Sarcopenia Muscle. 2024 May 16.  [Abstract]

    Immunofluorescence staining with EdU (red) and hoechst (blue) in porcine MuSCs treated with a series of concentrations of D-gal (0, 1, 5, 10, 20, 40 g/L; 48 h).

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    D-Galactose is a natural aldohexose and C-4 epimer of glucose.

    IC50 & Target

    Human Endogenous Metabolite

     

    Cellular Effect
    Cell Line Type Value Description References
    Caco-2 IC50
    12.5 mM
    Compound: Gal
    Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells
    Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells
    		[PMID: 17905738]
    In Vitro

    Galactose is important for the survival and virulence of bacteria. In Escherichia coli galactose is utilized by the Leloir pathway. Two anomers of d-galactose are used for different purposes, α-d-galactose as a carbon source and β-d-galactose for induction of UDP-galactose synthesis for biosynthetic glycosylation[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    D-Galactose Related Antibodies
    In Vivo

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    D-Galactose can be used in animal models to create subacute aging models in mice and cataract models in rats. Chronic D-galactose exposure induces neurodegeneration by enhancing caspase-mediated apoptosis and inhibiting neurogenesis and neuronal migration in mice, as well as increasing oxidative damage. Moreover, D-galactose-induced toxicity in mice serves as a useful model for studying the mechanisms of neurodegeneration and the evaluation of neuroprotective drugs and agents. Oral administration of D-galactose leads to cognitive impairment in rats, accompanied by oxidative damage. Cognitive impairments are observed in the open field test at the 4th and 6th weeks post-administration, and spatial memory deficits are noted in the radial arm maze test after the 6th week. D-Galactose is a classic agent for inducing subacute aging and cataract models. D-galactose alters protein and peptide structures by reacting with their free amino groups, leading to the accumulation of advanced glycation end-products (AGEs) during nonenzymatic glycation.

    Induction of subacute aging model[5]
    Background
    D-galactose changes the structure of protein and peptide by reacting with their free amine groups resulting in the accumulation of advanced glycation end (AGE) products through non-enzymatic glycation. AGEs give rise to age-related disorders. Rats and mice are generally used as animal models.
    Specific Modeling Methods
    Mice: C57BL/6J • female • 8-week-old
    Administration: 5, 100, 200 mg/day •s.c. • 8 weeks
    Modeling Indicators
    Body quality changes: Impaired spatial learning and memory of mice at a dose of 100 mg/kg.
    Induced locomotor impairment in LAT in a dose-dependent manner especially in the second day.

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: female C57BL/6J mice[5]
    Dosage: 50, 100 and 200 mg/kg/day, 8 weeks
    Administration: subcutaneous injection (s.c.)
    Result: Impaired spatial learning and memory of mice at a dose of 100 mg/kg.
    Induced locomotor impairment in LAT in a dose-dependent manner especially in the second day.
    Clinical Trial
    Molecular Weight

    180.16

    Formula

    C6H12O6
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C[C@@H]([C@H]([C@H]([C@@H](CO)O)O)O)O
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    H2O : 62.5 mg/mL (346.91 mM; ultrasonic and warming and heat to 60°C)

    DMSO : 50 mg/mL (277.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.5506 mL 27.7531 mL 55.5062 mL
    5 mM 1.1101 mL 5.5506 mL 11.1012 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (13.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (13.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 100 mg/mL (555.06 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.85%

    SDS (396 KB)

    COA (247 KB) HNMR (117 KB) RP-HPLC (243 KB) MS (68 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 5.5506 mL 27.7531 mL 55.5062 mL 138.7655 mL
    5 mM 1.1101 mL 5.5506 mL 11.1012 mL 27.7531 mL
    10 mM 0.5551 mL 2.7753 mL 5.5506 mL 13.8766 mL
    15 mM 0.3700 mL 1.8502 mL 3.7004 mL 9.2510 mL
    20 mM 0.2775 mL 1.3877 mL 2.7753 mL 6.9383 mL
    25 mM 0.2220 mL 1.1101 mL 2.2202 mL 5.5506 mL
    30 mM 0.1850 mL 0.9251 mL 1.8502 mL 4.6255 mL
    40 mM 0.1388 mL 0.6938 mL 1.3877 mL 3.4691 mL
    50 mM 0.1110 mL 0.5551 mL 1.1101 mL 2.7753 mL
    60 mM 0.0925 mL 0.4626 mL 0.9251 mL 2.3128 mL
    80 mM 0.0694 mL 0.3469 mL 0.6938 mL 1.7346 mL
    100 mM 0.0555 mL 0.2775 mL 0.5551 mL 1.3877 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    D-Galactose Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    D-Galactose59-23-4D-(+)-GalactoseEnvironmental PollutantsEndogenous MetaboliteEnvironmental ContaminantsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    D-Galactose
    Cat. No.:
    HY-N0210
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.